

type of report	Current report
number	54/2012
company	PHARMENA

Introduction of pre-emptive rights, allotment certificates, series C shares of Pharmena S.A. to trading on NewConnect market

The Management Board of PHARMENA S.A. informs that the Management Board of Warsaw Stock Exchange decided, in its resolution no. 877/2012 of 5th September 2012, to introduce to alternative trading system on the NewConnect market:

- 1) 6,254,260 (six million two hundred fifty-four thousand two hundred and sixty) pre-emptive rights to series C ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN each;
- 2) up to 781,782 (up to seven hundred eighty-one thousand seven hundred eighty-two) allotment certificates for series C ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN each, under the condition that such an issue of shares and their allotment is effected;
- 3) up to 781,782 (up to seven hundred eighty-one thousand seven hundred eighty-two) series C ordinary bearer shares of PHARMENA S.A. of a nominal value of 0.10 PLN each, under the condition that the increase of PHARMENA S.A. company's share capital carried out through the issue of new shares is registered.

In line with resolutions adopted during Extraordinary General Meeting of Pharmena S.A. of 21st August 2012, the funds obtained from the issue of series C and D shares will be assigned to clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA concerning bioavailability and phase II trials ("Proof of Concept") to confirm the efficacy of 1-MNA active substance with increased doses. The research will be carried out by Cortria Company.

The goal of the issue of series C shares is to obtain funds for production of tablets for clinical trials (bioavailability testing and phase II), as well as carrying out clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of bioavailability.

The issue of series D shares is planned for Q1 2013. Its goal is to obtain funds for clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of phase II ("Proof of Concept").

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board